Tag: RSH
Respiri raises $1.5m to fast-track wheezo commercialisation in multi-billion-dollar US market
Health technology company Respiri (ASX: RSH) has unveiled a A$1.5 million capital raising as it fast-tracks its expansion through the US respiratory health market, which is forecast to be worth US$85 ...
Respiri signs EAS Advisors to accelerate US market expansion
Asthma management specialist Respiri (ASX: RSH) has signed a deal with US boutique firm EAS Advisors LLC to accelerate its expansion into the North American market.
Respiri, which develops solution...
Respiri launches first reimbursed remote patient asthma monitoring program in US
Respiratory health management specialist Respiri (ASX: RSH) has launched its first reimbursed remote patient monitoring (RPM) pilot program involving flagship product wheezo at the Children’s Hospital...
Respiri launches telehealth and remote patient respiratory management program in Australia
Respiratory health technology company Respiri (ASX: RSH) is trialling a telehealth and remote patient management program in Australia that will also form the basis of the model for the US reimbursemen...
Respiri makes strategic appointments to facilitate UK wheezo launch
Days after obtaining Food and Drug Administration approval for sales of its wheezo device in the US, Respiri (ASX: RSH) has progressed its international expansion plans with strategic adviser appointm...
Respiri to sell wheezo device and technology in the United States after securing FDA approval
Wheezo device and app technology developer, Respiri (ASX: RSH) has received the greenlight from the United States Food and Drug Administration (FDA) to market and sell the technology as a class II med...
Respiri and Pharmacy Catalyst to begin wheezo in-pharmacy asthma patient program next month
Respiratory health focused Respiri (ASX: RSH) has bedded-in support for its wheezo device and technology after Pharmacy Platform member Pharmacy Catalyst confirmed it will begin the wheezo in-pharmacy...
Respiri teams up with Pharmacy 4 Less group for wheezo sales
Respiratory health technology company Respiri (ASX: RSH) has announced a new sales and marketing partnership with the Pharmacy 4 Less group for the sale of its asthma management device wheezo commenci...
Respiri orders up on growing demand for wheezo device, announces new brand partnership
Demand for Respiri’s (ASX: RSH) wheezo asthma management device has continued to grow following the platform’s recent commercial launch in Australia with sales orders increasing and a new banner partn...
Respiri’s wheezo logo scores prime position on Carlton AFLW uniforms
Three months after announcing the start of a co-major partnership with Carlton Football Club, health technology developer Respiri (ASX: RSH) has revealed its product logo will adorn the club’s officia...
Respiri shaves costs as wheezo technology continues to be well-received
With Respiri’s (ASX: RSH) stage launch of wheezo across select Australian pharmacies and online underway, the company has revealed further major cost reductions resulting in improved margins.
The c...
Respiri ‘pleased’ with wheezo feedback from initial sales and marketing
Respiratory health management company Respiri (ASX: RSH) has updated the market regarding the preliminary release of its wheezo platform and device, saying it was “very pleased” with the responses it ...
Respiri files new patent application for wheezo asthma management device
Respiratory-focused eHealth company Respiri (ASX: RSH) has filed an additional patent application based on recent improvements made to the algorithm for its wheezo asthma management device.
The new...
Respiri raises $12.5 million to commercialise wheezo asthma device
eHealth company Respiri (ASX: RSH) has completed a $12.5 million capital raising targeted at the commercial launch of its proprietary wheezo asthma management platform in Australia before year end.
...
Respiri engages Entech Electronics to manufacture wheezo at ‘significantly’ improved cost
Health technology company Respiri (ASX: RSH) has engaged Entech Electronics to manufacture its “ground breaking” wheezo device offshore in China, which is expected to “significantly improve” productio...
Respiri unveils promising wheezo clinical study results
Preliminary results of a clinical study involving the wheezo asthma management platform made by eHealth technology developer Respiri (ASX: RSH) has shown the device is capable of accurately detecting ...
Respiri teams up with Carlton Football Club to promote wheezo device
A day after publishing its full year accounts, eHealth company Respiri (ASX: RSH) has tentatively set foot in Australian rules football courtesy of a partnership with Carlton Football Club AFLW, comme...
Respiri signs referral agreement with APA to proliferate wheezo in Australia
eHealth company Respiri (ASX: RSH) has taken another step towards growing sales of its wheezo device ahead of its October launch, after signing a three-year product referral agreement (PRA) with the A...
Respiri partners with Australian Patients Association for wheezo study
eHealth Software-as-a-Service (Saas) company Respiri (ASX: RSH) has updated the market with news it has entered into a partnership with the Australian Patients Association (APA) to support asthma suff...
eHealth SaaS provider Respiri targets $6-8m revenue for 2021
eHealth technology developer and maker of the wheezo device, Respiri (ASX: RSH) has published interim revenue guidance for 2021 with total revenues from both device and software subscription estimated...
Respiri accelerates wheezo commercialisation by teaming up with BNPL company Zip
Wheezo developer Respiri’s (ASX: RSH) commercialisation path will accelerate even further after the company collared a deal with renowned buy now pay later provider Zip Co Ltd (ASX: Z1P).
Respiri c...
